Sparstolonin B Inhibits Pro-Angiogenic Functions and Blocks Cell Cycle Progression in Endothelial Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Bateman, Henry R ^a   Liang, Qiaoli ^a,b   Fan, Daping ^a   Rodriguez, Vanessa ^c   Lessner, Susan M ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c South Carolina Governor School for Science and Mathematics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 6; CYCLIN E; CYCLIN E2; SPARSTOLONIN B; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE PROTEIN 6 GENE; CELL CYCLE S PHASE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN E2 GENE; DRUG MECHANISM; ENDOTHELIUM CELL; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; CYCLINS; ENDOTHELIAL CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84881108823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070500     Document Type: Article

References (29)

1. Qiu C, Xu X, Zhu H, (2008) The studies on the anti-inflammatory and analgesia effects of SLW. Pharmacology and Clinics of Chinese Materia Medica 14: 7-10.
2. Xiong Y, Deng KZ, Guo YQ, Gao WY, Zhang TJ, (2009) New chemical constituents from the rhizomes of Sparganium stoloniferum. Arch Pharm Res 32: 717-720.
3. Liang Q, Wu Q, Jiang J, Duan J, Wang C, et al. (2011) Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem 286: 26470-26479.
4. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
5. Risau W, (1997) Mechanisms of angiogenesis. Nature 386: 671-674.
6. Staton CA, Reed MW, Brown NJ, (2009) A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 90: 195-221.
7. Bussolino F, Mantovani A, Persico G, (1997) Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22: 251-256.
8. Carmeliet P, (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
9. Liekens S, De Clercq E, Neyts J, (2001) Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61: 253-270.
10. Pandya NM, Dhalla NS, Santani DD, (2006) Angiogenesis-a new target for future therapy. Vascul Pharmacol 44: 265-274.
11. Wu Z, Cho H, Hampton GM, Theodorescu D, (2009) Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia 11: 66-76.
12. Borlado LR, Mendez J, (2008) CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 29: 237-243.
13. Nigg EA, (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32.
14. Sullivan M, Morgan DO, (2007) Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8: 894-903.
15. Tassan JP, Schultz SJ, Bartek J, Nigg EA, (1994) Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol 127: 467-478.
16. O'Farrell PH, (2001) Triggering the all-or-nothing switch into mitosis. Trends Cell Biol 11: 512-519.
17. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 399: 271-275.
18. Meng H, Xing G, Sun B, Zhao F, Lei H, et al. (2010) Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 4: 2773-2783.
19. Rohde LE, Lee RT, (2003) Pathophysiology of atherosclerotic plaque development and rupture: an overview. Semin Vasc Med 3: 347-354.
20. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, et al. (2012) Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys 527: 81-89.
21. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, et al. (2006) Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118: 2711-2720.
22. Wang XH, Wu SY, Zhen YS, (2004) Inhibitory effects of emodin on angiogenesis. Yao Xue Xue Bao 39: 254-258.
23. Hsu WH, Lee BH, Pan TM, (2010) Red mold dioscorea-induced G2/M arrest and apoptosis in human oral cancer cells. J Sci Food Agric 90: 2709-2715.
24. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, et al. (2007) Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 177: 253-264.
25. Liu F, Li X, Wang C, Cai X, Du Z, et al. (2009) Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 125: 2511-2519.
26. Wang Q, Zou L, Liu W, Hao W, Tashiro S, et al. (2011) Inhibiting NF-kappaB activation and ROS production are involved in the mechanism of silibinin's protection against D-galactose-induced senescence. Pharmacol Biochem Behav 98: 140-149.
27. Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S, (2008) NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 27: 53.
28. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS, (2004) Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 94: 262-268.
29. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H, (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224.